Lead Product(s) : AAZ
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The paper reveals DLX-1—a new compound inspired by the chemical structures of common psychedelic substances that demonstrates sustained antidepressant effects but without hallucinogenic properties.
Brand Name : DLX-1
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2021
Lead Product(s) : AAZ
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?